Y-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial of GD2-SADA

NEW YORK, April 05, 2023 -- Y-mAbs Therapeutics, Inc. a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products... | April 5, 2023

Related Keywords

Russia ,Ukraine ,New York ,United States ,Memorial Sloan Kettering Cancer Center ,Nai Kong Cheung ,Globenewswire Inc ,Quarterly Reports On Firm ,Massachusetts Institute Of Technology ,Y Mabs Therapeutics Inc ,Abs Therapeutics ,Sloan Kettering Cancer Center ,Kong Cheung ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,Y Mabs Therapeutics ,Nc Stock Exchange ,News ,Information ,Press Release ,Few ,Pril ,023 ,Iopharmaceutical ,Company ,Ocused ,N ,The ,Development ,End ,Ommercialization ,F ,Herapeutic Ymab Us9842411095 ,